22Dec
Cadent Therapeutics Acquired by Novartis for Up to $770 Million
Cadent Therapeutics, a Cambridge, Massachusetts-based, privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders, announced on December 17, 2020, that Novartis will acquire all of the outstanding capital stock of Cadent Therapeutics....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
More than thirty years ago, the Washington Supreme Court ruled defense counsel may not engage in ex ...
Read More >
In the spirit of the upcoming Super Bowl, it is important to keep in mind certain rules of play rega...
Read More >
Does a position that a company is holding for an employee out on FMLA leave an “open position” as ...
Read More >
Trends in Mergers and Acquisitions“What’s market?” is an important question for the buyer and sel...
Read More >
PERM can be one of the most confusing and frustrating portions of the employment-based Green Card pr...
Read More >
On November 8, 2019, the Federal Trade Commission (“FTC”) and the Antitrust Division of the U.S. D...
Read More >